1. Mosaicism in Fanconi anemia: concise review and evaluation of published cases with focus on clinical course of blood count normalization

   • Eileen Nicoletti
   • Gayatri Rao
   • Jonathan D. Schwartz

   Review Article Open access 17 February 2020 Pages: 913 - 924

   

2. Pathophysiology and recent therapeutic insights of sickle cell disease

   • Firdosh Shah
   • Mitesh Dwivedi

   Review Article 10 March 2020 Pages: 925 - 935

   

3. Oxidative stress assessment in sickle cell anemia patients treated with hydroxyurea

   • Cristiane O. Renó
   • Amanda Rodrigues Barbosa
   • Hérica L. Santos

   Original Article 12 March 2020 Pages: 937 - 945

   

4. High levels of proinflammatory cytokines IL-6 and IL-8 are associated with a poor clinical outcome in sickle cell anemia

   • Igor F. Domingos
   • Diego A. Pereira-Martins
   • Magnun N. N. Santos

   Original Article 05 March 2020 Pages: 947 - 953

   

5. Targeted next-generation sequencing identified novel mutations associated with hereditary anemias in Brazil

   • M. C. C. M. Svidnicki
   • G. K. Zanetta
   • S. T. O. Saad

   Original Article Open access 23 March 2020 Pages: 955 - 962

   

6. Elevated serum myoglobin levels at hospital admission and the risk of early death among patients with hemophagocytic lymphohistiocytosis: evidence from 155 pediatric patients

   • Xun Li
   • Haipeng Yan
   • Xiulan Lu

   Original Article 27 March 2020 Pages: 963 - 971

   

7. Safety and efficacy of arsenic trioxide and all-trans retinoic acid therapy in acute promyelocytic leukemia patients with a high risk for early death

   • Gi-June Min
   • Byung-Sik Cho
   • Hee-Je Kim

   Original Article 08 April 2020 Pages: 973 - 982

   

8. JAK2 exon 12 mutations in cases with JAK2V617F-negative polycythemia vera and primary myelofibrosis

   • Madhavi Maddali
   • Uday Prakash Kulkarni
   • Poonkuzhali Balasubramanian

   Original Article 10 April 2020 Pages: 983 - 989

   

9. Separase activity distribution can be a marker of major molecular response and proliferation of CD34⁺ cells in TKI-treated chronic myeloid leukemia patients

   • Birgit Spiess
   • Helga Kleiner
   • Wolfgang Seifarth

   Original Article Open access 06 April 2020 Pages: 991 - 1006

   

10. Association between myelofibrosis and risk of non-hematologic malignancies: a population-based retrospective cohort study

    • Walid Saliba
    • Maria Khudyakova
    • Meir Preis

    Original Article 10 March 2020 Pages: 1007 - 1016

    

11. Genetic polymorphisms and multiple myeloma risk: a meta-analysis

    • Pengcheng Zhang
    • Bing Liu

    Original Article 11 March 2020 Pages: 1017 - 1024

    

12. Significant differences in access to tests and treatments for multiple myeloma between public and private systems in Latin America. Results of a Latin American survey. GELAMM (Grupo de Estudio Latino Americano de Mieloma Múltiple)

    • Eloísa Riva
    • N. Schütz
    • D. Fantl

    Original Article 10 March 2020 Pages: 1025 - 1030

    

13. Clinical outcomes and prognostic factors in patients with multiple myeloma in South Tyrol: a retrospective single-center analysis

    • Maximilian Mair
    • Christian Straka
    • Dominic Fong

    Original Article 05 March 2020 Pages: 1031 - 1040

    

14. DCEP and bendamustine/prednisone as salvage therapy for quad- and penta-refractory multiple myeloma

    • Scott R. Goldsmith
    • Mark A. Fiala
    • Ravi Vij

    Original Article 04 March 2020 Pages: 1041 - 1048

    

15. Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma

    • Evangelos Terpos
    • Karthik Ramasamy
    • Roman Hajek

    Original Article 01 April 2020 Pages: 1049 - 1061

    

16. Continuous lenalidomide treatment after bortezomib-melphalan-prednisolone therapy for newly diagnosed multiple myeloma

    • Tadao Ishida
    • Hideo Kimura
    • Kazuyuki Shimizu

    Original Article 04 April 2020 Pages: 1063 - 1072

    

17. Radioimmunotherapy for mantle cell lymphoma: 5-year follow-up of 90 patients from the international RIT registry

    • Karin Hohloch
    • Christine Windemuth-Kieselbach
    • Christian W. Scholz

    Original Article Open access 03 March 2020 Pages: 1073 - 1079

    

18. Possible hampered effectiveness of second-line treatment with rituximab-containing chemotherapy without signs of rituximab resistance: a population-based study among patients with chronic lymphocytic leukemia

    • Lina van der Straten
    • Arnon P. Kater
    • Mark-David Levin

    Original Article 19 March 2020 Pages: 1081 - 1091

    

19. Comprehensive immunohistochemical analysis of immune checkpoint molecules in adult T cell leukemia/lymphoma

    • Mai Takeuchi
    • Hiroaki Miyoshi
    • Koichi Ohshima

    Original Article 10 March 2020 Pages: 1093 - 1098

    

20. Influence of HLA 1–3-locus mismatch and antithymocyte globulin administration in unrelated bone marrow transplantation

    • Koji Kawamura
    • Junya Kanda
    • Yoshinobu Kanda

    Original Article 23 March 2020 Pages: 1099 - 1110

    

21. Serum albumin and C-reactive protein as significant predictors of non-relapse mortality in lower gastrointestinal graft-versus-host disease

    • Haerim Chung
    • Ji Eun Jang
    • June-Won Cheong

    Original Article 06 April 2020 Pages: 1111 - 1119

    

22. Histological and magnified endoscopic evaluation of villous atrophy in gastrointestinal graft-versus-host disease

    • Kana Matsuda
    • Shoko Ono
    • Naoya Sakamoto

    Original Article 04 March 2020 Pages: 1121 - 1128

    

23. Successful use of venetoclax for treatment of eosinophilic dermatosis of myeloproliferative disease in a patient with chronic lymphocytic leukemia

    • Gopisree Peringeth
    • Suchitra Sundaram
    • Pallawi Torka

    Letter to the Editor 19 March 2020 Pages: 1129 - 1131

    

24. Molecular remission using three monoclonal antibodies followed by allogeneic bone marrow transplantation in an infant with refractory ALL

    • Bernd Gruhn
    • Grit Brodt
    • Jana Ernst

    Letter to the Editor Open access 18 February 2020 Pages: 1133 - 1134

25. Residual disease by flow cytometry in patients with nucleophosmin-mutated acute myeloblastic leukemia

    • Marc Sorigue
    • Andrea Espasa
    • Jordi Junca

    Letter to the Editor 13 March 2020 Pages: 1135 - 1136

26. Risk factors associated with early viral reactivation following haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide: a pilot study

    • Jordan Baskett
    • Kathryn A. Culos
    • Katie S. Gatwood

    Letter to the Editor 06 March 2020 Pages: 1137 - 1139

27. Rapid response to a single-dose rituximab combined with bortezomib in refractory and relapsed warm autoimmune hemolytic anemia

    • Miao Chen
    • Junling Zhuang
    • Bing Han

    Letter to the Editor 07 March 2020 Pages: 1141 - 1143

28. A 19-year-old patient with atypical chronic myeloid leukemia

    • Philipp Ernst
    • Björn Engmann
    • Inken Hilgendorf

    Letter to the Editor Open access 19 March 2020 Pages: 1145 - 1148

    

29. Current IST-free/relapse-free survival as a new endpoint after allogeneic hematopoietic stem cell transplantation

    • Roberto Crocchiolo
    • Alessio Signori
    • Mauricette Michallet

    Letter to the Editor 17 March 2020 Pages: 1149 - 1150

    

30. Rectal involvement in pre-early T acute lymphoblastic leukemia

    • Roberto Massaiu
    • Francesco Longu
    • Claudio Fozza

    Letter to the Editor 16 March 2020 Pages: 1151 - 1152

    

31. The clinical significance of the prognostic nutritional index in very elderly patients over 80 years of age with diffuse large B-cell lymphoma

    • Erina Hamada
    • Ogura Shinji
    • Tomonori Nakazato

    Letter to the Editor 08 April 2020 Pages: 1153 - 1155

    

32. Successful treatment of intracranial Rosai-Dorfman disease with cytarabine and dexamethasone: case report and review of literature

    • Wei Wang
    • Jian Sun
    • Daobin Zhou

    Letter to the Editor 31 March 2020 Pages: 1157 - 1159